---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035860"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:11:32.335423+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint

## Summary
- Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.
- No significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms.
- PIPE-307 demonstrated acceptable safety and tolerability at both doses.
- Company will continue to analyze exploratory endpoints and plans future medical meeting presentation.
- CEO and CMO express disappointment; focus remains on inflammatory and fibrotic disease pipeline.

## SEC filing metadata
- accession: 0001437749-25-035860
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925035860/0001437749-25-035860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925035860/ctnm20251117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035860
- JSON: https://secwatch.observer/filing/0001437749-25-035860.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.